ResearcherErciyes UniversityActive in the last 2 years
Metin Özkan
Matched on ORCID iD 0000-0003-0359-0504; OpenAlex author ID A5037670666, A5142773062. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2012: 3 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- The Global Immune-Nutrition-Inflammation Index Is Associated with Survival Outcomes and Enhances Prognostic Discrimination in Metastatic Pancreatic Cancer. Last author DOI 10.3390/medicina62071279↗
- Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gem… Co-author DOI 10.1186/s12885-020-06758-9↗
- XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Co-author DOI 10.5754/hge12181↗
- Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Med… Co-author DOI 10.7314/apjcp.2012.13.5.1841↗
- Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multic… Co-author PMID 22517701↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kamuran Yuceer · 1 shared paper, 2026 · strength 0.43
- Nuriye Özdemir · 4 shared papers, 2012–2020 · strength 0.16
- Paper Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated wi… DOI 10.1186/s12885-020-06758-9↗
- Paper XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. DOI 10.5754/hge12181↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Abdurrahman Işıkdoğan · 3 shared papers, 2012–2020 · strength 0.14
- Paper Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated wi… DOI 10.1186/s12885-020-06758-9↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Nuri Faruk Aykan · 1 shared paper, 2020 · strength 0.09
- Saadettin Kılıçkap · 1 shared paper, 2020 · strength 0.09
- Türkkan Evrensel · 1 shared paper, 2020 · strength 0.09
- Şuayib Yalçın · 1 shared paper, 2020 · strength 0.09
- Velı Berk · 3 shared papers, 2012 · strength 0.08
- Paper XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. DOI 10.5754/hge12181↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Ali̇ İnal · 3 shared papers, 2012 · strength 0.08
- Paper XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. DOI 10.5754/hge12181↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Fahriye Tuğba Köş · 2 shared papers, 2012 · strength 0.05
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Mahmut Gümüş · 2 shared papers, 2012 · strength 0.05
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Olçun Ümit Ünal · 1 shared paper, 2012 · strength 0.03
- Özlem Sönmez · 1 shared paper, 2012 · strength 0.03
- Gamze Göksel Ozturk · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.